Upadacitinib Found Effective in Achieving Remission in Crohn Disease, Including Biologic-Experienced Patients
April 25, 2025

In a real-world study of patients with Crohn disease, upadacitinib achieved 52.1% clinical remission at 12 weeks and 42.7% endoscopic remission at 6 months, with no new safety concerns reported.

Endemic Measles is a Clear and Present Danger, According to Stanford University Modeling Study
April 25, 2025

At current vaccination rates, measles could become endemic in the US again within 21 years; the threat extends to rubella, polio, and diphtheria, the study found.

Postpartum Hormonal Contraceptive Use Linked to Increased Risk of Depression
April 25, 2025

The increased risk of depression when oral contraceptives were started following childbirth was "instantaneous," researchers wrote, and was ~50% greater than nonuse.

Precision Obesity Medicine Breakthroughs To Lead DDW 2025 Presentations from Phenomix Sciences
April 25, 2025

Phenomix will showcase new data on prediction of adverse events to GLP-1 RA therapy, a new obesity sub-phenotype, and approaches to improve surgical outcomes.

Oral Semaglutide Cuts MACE Risk by 14% in High-Risk Adults: Daily Dose
April 25, 2025

Your daily dose of the clinical news you may have missed.

The Role for CGM in Glycemic Management Will Continue to Expand, Including in Prediabetes, Expert Says
April 25, 2025

CGM is now standard of care in T1D and evidence is solid for a role in insulin-treated T2D; Thomas Martens, MD, shares thoughts on CGM growth in the next 3-5 years.

New-Onset Type 2 Diabetes Tied to Higher Risk of Specific Obesity-Related Cancers
April 24, 2025

New data to be presented at ECO 2025 shows new-onset T2D is linked to increased risk of liver, pancreatic, and bowel cancers, but not endometrial or post-menopausal breast cancer.

How to Maximize CGM Data Presented in the Ambulatory Glucose Profile: Thomas Martens, MD, Illustrates
April 24, 2025

Martens, medical director of the International Diabetes Center (IDC) in Minneapolis, highlights an IDC resource that helps target problem areas in management of hyperglycemia.

Investigational Probiotic Drug Gains FDA Support for Phase 2 Obesity Trial
April 24, 2025

Northstrive Biosciences received positive FDA feedback for its IND application for EL-22, a probiotic-based treatment for obesity.

Smoking Rates Hit New Low, But Cervical Cancer Screening Still Lags: 2025 ACS Report
April 24, 2025

While smoking in the US continues to decline, the American Cancer Society reports mixed progress in major cancer risk factors, prevention, and screening.